Salarius Pharmaceuticals, Inc. SLRX
We take great care to ensure that the data presented and summarized in this overview for Salarius Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SLRX
Top Purchases
Top Sells
About SLRX
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Insider Transactions at SLRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Feb 13
2023
|
Mark J Rosenblum Exec VP Finance, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
6,432
+22.74%
|
-
|
|
Feb 13
2023
|
David J. Arthur Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,300
+22.95%
|
-
|
|
Jan 03
2023
|
Jonathan I Lieber Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,440
+32.88%
|
-
|
|
Jan 03
2023
|
Paul Lammers Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,440
+45.6%
|
-
|
|
Jan 03
2023
|
Arnold C Hanish Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,440
+50.0%
|
-
|
|
Jan 03
2023
|
Bruce J Mc Creedy Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,440
+44.61%
|
-
|
|
Jan 03
2023
|
William K. Mc Vicar Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,440
+44.61%
|
-
|
|
Jan 03
2023
|
Tess Burleson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,440
+34.6%
|
-
|
|
Jan 03
2023
|
David J. Arthur Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+37.23%
|
-
|
|
Jan 03
2023
|
Mark J Rosenblum Exec VP Finance, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+34.16%
|
-
|
|
Nov 03
2022
|
Mark J Rosenblum Exec VP Finance, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
7,314
+4.49%
|
$7,314
$1.73 P/Share
|
|
Nov 03
2022
|
David J. Arthur Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+3.38%
|
$10,000
$1.73 P/Share
|
|
Jun 07
2022
|
Jonathan I Lieber Director |
BUY
Open market or private purchase
|
Direct |
37,500
+50.0%
|
$0
$0.19 P/Share
|
|
Jun 07
2022
|
Tess Burleson Director |
BUY
Open market or private purchase
|
Direct |
27,700
+46.36%
|
$0
$0.18 P/Share
|
|
Jun 06
2022
|
William K. Mc Vicar Director |
BUY
Open market or private purchase
|
Indirect |
26,553
+50.0%
|
$0
$0.19 P/Share
|
|
Jun 03
2022
|
Arnold C Hanish Director |
BUY
Open market or private purchase
|
Indirect |
28,000
+37.66%
|
$0
$0.18 P/Share
|
|
May 31
2022
|
Mark J Rosenblum Exec VP Finance, CFO |
BUY
Open market or private purchase
|
Direct |
28,000
+15.88%
|
$0
$0.18 P/Share
|
|
May 26
2022
|
David J. Arthur Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
21,900
+2.37%
|
$0
$0.18 P/Share
|
|
May 26
2022
|
David J. Arthur Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
22,000
+3.74%
|
$0
$0.18 P/Share
|
|
May 03
2022
|
Mark J Rosenblum Exec VP Finance, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+7.67%
|
$0
$0.19 P/Share
|